Eculizumab and recurrent C3 glomerulonephritis

Pediatric Nephrology

Volumn 28, Issue 10, 2013, Pages 1975-1981

  Gurkan, Sevgi ^a   Fyfe, Billie ^a   Weiss, Lynne ^a   Xiao, Xue ^b   Zhang, Yuzhou ^b   Smith, Richard J ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

C3 Glomerulonephritis; Eculizumab; Renal transplant

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; ECULIZUMAB; NEPHRITIC FACTOR; PREDNISONE; TACROLIMUS;

ADULT; ALLOGRAFT; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; C3 GLOMERULONEPHRITIS; CASE REPORT; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT SYSTEM; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; GENETIC SCREENING; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOMODULATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MUTATION; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; TREATMENT DURATION; URINALYSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT PATHWAY, ALTERNATIVE; DRUG ADMINISTRATION SCHEDULE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; PATIENT SELECTION; RECURRENCE; REOPERATION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883261341     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2503-y     Document Type: Article

References (27)

1. Habib R, Kleinknecht C, Gubler MC, Maiz HB (1973) Idiopathic membranoproliferative glomerulonephritis. Morphology and natural history. Perspect Nephrol Hypertens 1:491-514
2. Strife CF, McEnery PT, McAdams AJ, West CD (1977) Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 7:65-72
3. Levy M, Gubler MC, Sich M, Beziau A, Habib R (1978) Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (type I MPGN). Clin Immunol Immunopathol 10:477-492
4. Fakhouri F, Fremeaux-Bacchi V, Noel LH, Cook HT, Pickering MC (2010) C3 glomerulopathy: a new classification. Nat Rev Nephrol 6:494-499
5. Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grunfeld JP, Lesavre P, Noel LH, Fakhouri F (2007) Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44:193-199
6. Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, Cramer C, Nester CM, Smith RJ (2011) Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 6:1009-1017
7. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD (2009) Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 4:22-32
8. Vivarelli M, Pasini A, Emma F (2012) Eculizumab for the treatment of dense deposit disease. N Engl J Med 366:1163-1165
9. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7:748-756
10. Daina E, Noris M, Remuzzi G (2012) Eculizumab in a patient with dense deposit disease. N Engl J Med 366:1161-1163
11. McCaughan JA, O'Rourke DM, Courtney AE (2012) Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 12:1046-1051
12. Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, Jozsi M, Zipfel PF, Hageman GS, Smith RJ (2006) Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 43:582-589
13. Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, Katz LM, Sethi S, Smith RJ (2012) Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 7:265-274
14. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31:E1445-E1460
15. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R (2007) Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 92:1695-1698
16. Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R (2010) Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 85:329-334
17. Sethi S, Nester CM, Smith RJ (2012) Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 81:434-441
18. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, Rodriguez de Cordoba S (2010) Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120:3702-3712
19. Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Fremeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC (2010) Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376:794-801
20. Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, Kirschfink M, Hoppe B, Zipfel PF, Licht C (2009) C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 75:1230-1234
21. Smith RJ, Harris CL, Pickering MC (2011) Dense deposit disease. Mol Immunol 48:1604-1610
22. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J (1983) Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 74:175-192
23. Schena FP, Pertosa G, Stanziale P, Vox E, Pecoraro C, Andreucci VE (1982) Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis. Clin Nephrol 18:240-246
24. Schwertz R, Rother U, Anders D, Gretz N, Scharer K, Kirschfink M (2001) Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol 12:166-172
25. Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P (2011) Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 6:1488-1494
26. Parker C (2009) Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373:759-767
27. Kose O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nurnberger J (2010) New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 36:669-672